Tech Company Inital Public Offerings

Ra Pharmaceuticals IPO

Headquartered in Cambridge, Ra Pharmaceuticals is now a public company.

Transaction Overview

Company Name
Announced On
10/26/2016
Transaction Type
IPO
Amount
$91,000,000
Proceeds Purpose
We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows: approximately $33.0 million to fund clinical development of RA101495 through the completion of a Phase 2 clinical trial in PNH patients; approximately $11.0 million to fund a Phase 2 clinical trial in rMG patients and a Phase 1b clinical trial in LN patients; approximately $18.9 million to advance our pipeline programs in Factor D, oral C5 inhibition and C1s; and the remainder, if any, for working capital and other general corporate purposes.

Company Information

Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
87 Cambridge Park Dr.
Cambridge, MA 02140
USA
Email Address
Overview
Ra Pharmaceuticals is developing Cyclomimetics, a new drug class with the diversity and specificity of antibodies, coupled with the many benefits of small molecules. Ra Pharma's peptide-like molecules are highly-stable, synthetic products with chemical structures that offer intrinsic cell permeability.
Profile
Ra Pharmaceuticals LinkedIn Company Profile
Social Media
Ra Pharmaceuticals Company Twitter Account
Company News
Ra Pharmaceuticals News
Facebook
Ra Pharmaceuticals on Facebook
YouTube
Ra Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Doug Treco
  Doug Treco LinkedIn Profile  Doug Treco Twitter Account  Doug Treco News  Doug Treco on Facebook
Chief Financial Officer
David Lubner
  David Lubner LinkedIn Profile  David Lubner Twitter Account  David Lubner News  David Lubner on Facebook
Chief Medical Officer
Ramin Farzaneh-Far
  Ramin Farzaneh-Far LinkedIn Profile  Ramin Farzaneh-Far Twitter Account  Ramin Farzaneh-Far News  Ramin Farzaneh-Far on Facebook
Chief Scientific Officer
Simon Read
  Simon Read LinkedIn Profile  Simon Read Twitter Account  Simon Read News  Simon Read on Facebook
VP - R & D
Alonso Ricardo
  Alonso Ricardo LinkedIn Profile  Alonso Ricardo Twitter Account  Alonso Ricardo News  Alonso Ricardo on Facebook


 

 

Browse more venture capital transactions:

Prev: 10/26/2016: OpenDataSoft venture capital transaction
Next: 10/26/2016: AvidXchange venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on every notable VC transaction. VC transactions reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary